PMP
MCID: PSD007
MIFTS: 48

Pseudomyxoma Peritonei (PMP) malady

Categories: Rare diseases, Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Pseudomyxoma Peritonei

Aliases & Descriptions for Pseudomyxoma Peritonei:

Name: Pseudomyxoma Peritonei 12 50 56 52 42 14 69
Pmp 50 56
Syndrome of Pseudomyxoma Peritonei 50
Gelatinous Ascites 56
Mucinous Ascites 12
Adenomucinosis 56

Characteristics:

Orphanet epidemiological data:

56
pseudomyxoma peritonei
Prevalence: 1-9/1000000 (Worldwide); Age of onset: Adult; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:3559
MeSH 42 D011553
NCIt 47 C3345
SNOMED-CT 64 112679004 307601000
Orphanet 56 ORPHA26790
MESH via Orphanet 43 D011553
UMLS via Orphanet 70 C0033822
ICD10 via Orphanet 34 C78.6
UMLS 69 C0033822

Summaries for Pseudomyxoma Peritonei

NIH Rare Diseases : 50 pseudomyxoma peritonei (pmp) is a rare condition characterized by the presence of mucin in the abdominal (peritoneal) cavity. while the most common cause of pmp is appendix cancer, several types of tumors (including non-cancerous tumors) can cause pmp. signs and symptoms may include an increase in abdominal size or bloating; inguinal hernia (in men); an ovarian mass, felt during a routine pelvic exam (in women); pain or discomfort in the abdomen; and/or appendicitis. treatment depends on the underlying cause of the condition (the location and type of the original tumor, including whether it is malignant) and the extent of spreading. a combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is often the most successful treatment, and can achieve overall survival outcomes of up to 84% at 5 years. last updated: 12/28/2016

MalaCards based summary : Pseudomyxoma Peritonei, also known as pmp, is related to colorectal cancer and mucinous adenocarcinoma, and has symptoms including constipation, abdominal pain and nausea and vomiting. An important gene associated with Pseudomyxoma Peritonei is MUC2 (Mucin 2, Oligomeric Mucus/Gel-Forming), and among its related pathways/superpathways are Cytoskeletal Signaling and O-linked glycosylation. The drugs Cisplatin and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include appendix, colon and small intestine.

Disease Ontology : 12 An appendix cancer that is characterized by progressive accumulation of mucus-secreting tumor cells within the abdomen and pelvis.

Wikipedia : 71 Pseudomyxoma peritonei (PMP) is a clinical condition caused by cancerous cells (mucinous adenocarcinoma)... more...

Related Diseases for Pseudomyxoma Peritonei

Diseases related to Pseudomyxoma Peritonei via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 204)
id Related Disease Score Top Affiliating Genes
1 colorectal cancer 28.3 CDX2 KRAS KRT20 KRT7 MUC1 MUC2
2 mucinous adenocarcinoma 11.5
3 gelatinous ascites 11.4
4 handl syndrome 10.8
5 peritonitis 10.6
6 adenocarcinoma 10.5
7 cystadenocarcinoma 10.4
8 teratoma 10.3
9 mucinous cystadenocarcinoma 10.3
10 radiculopathy 10.3 KRT20 KRT7
11 adult myxoid chondrosarcoma 10.3 KRT20 KRT7
12 ascending colon cancer 10.3 KRT20 MUC2
13 bronchus mucoepidermoid carcinoma 10.3 KRT20 KRT7
14 steroid-induced glaucoma - borderline 10.3 KRT20 KRT7
15 non specific chronic endometritis 10.3 KRT20 KRT7
16 nonossifying fibromyxoid tumor 10.3 KRT20 KRT7
17 spasmodic dysphonia 10.3 KRT20 KRT7
18 waterhouse-friderichsen syndrome 10.2 KRT20 KRT7
19 synovitis 10.2 CDX2 KRT7
20 cystic teratoma 10.2
21 degenerative myopia 10.2 KRT20 KRT7
22 exposure keratitis 10.2 CDX2 MUC2
23 paraphimosis 10.2 KRT20 KRT7
24 vulva squamous cell carcinoma 10.2 KRT20 KRT7
25 peripheral nervous system ganglioneuroblastoma 10.2 CDX2 KRT7
26 klatskin's tumor 10.2 KRT20 KRT7
27 extramedullary plasmacytoma 10.2 CDX2 KRT20
28 acute eustachian salpingitis 10.2 CDX2 MUC2
29 neuroendocrine tumor 10.2 CDX2 KRT20
30 maternally-inherited cardiomyopathy and hearing loss 10.2 MUC2 MUC5AC
31 cystadenoma 10.2
32 mucinous adenocarcinoma of the appendix 10.2
33 osteosarcoma arising in bone paget's disease 10.2 KRT7 MUC5AC
34 sensory organ benign neoplasm 10.2 KRT20 KRT7
35 rectum lymphoma 10.2 KRT20 KRT7
36 breast adenocarcinoma 10.2 KRT7 MUC5AC
37 porencephaly, cerebellar hypoplasia, and internal malformations 10.2 MUC2 MUC5AC
38 bilateral hypoactive labyrinth 10.2 KRAS KRT7
39 sarcomatoid basal cell carcinoma 10.2 KRT20 KRT7
40 inguinal hernia 10.2
41 strabismus 10.2 MUC2 MUC5AC
42 ovarian squamous cell carcinoma 10.1 KRT20 MUC6
43 cervix endometriosis 10.1 CDX2 KRT20 MUC2
44 peritoneal benign neoplasm 10.1 CDX2 KRT20 KRT7
45 dystonia 10.1 CDX2 KRT20 KRT7
46 plasmacytoma 10.1 KRAS KRT7
47 anal canal paget's disease 10.1 CDX2 KRT20 KRT7
48 endometriosis 10.1
49 apocrine adenocarcinoma 10.1 CDX2 KRT20 KRT7
50 mucosal melanoma 10.1 CDX2 KRT20 KRT7

Graphical network of the top 20 diseases related to Pseudomyxoma Peritonei:



Diseases related to Pseudomyxoma Peritonei

Symptoms & Phenotypes for Pseudomyxoma Peritonei

Human phenotypes related to Pseudomyxoma Peritonei:

56 32 (show all 12)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 constipation 56 32 Occasional (29-5%) HP:0002019
2 abdominal pain 56 32 Occasional (29-5%) HP:0002027
3 nausea and vomiting 56 32 Occasional (29-5%) HP:0002017
4 respiratory insufficiency 56 32 Occasional (29-5%) HP:0002093
5 ascites 56 32 Very frequent (99-80%) HP:0001541
6 weight loss 56 32 Occasional (29-5%) HP:0001824
7 hernia 56 32 Occasional (29-5%) HP:0100790
8 inflammation of the large intestine 56 32 Frequent (79-30%) HP:0002037
9 intestinal obstruction 56 32 Occasional (29-5%) HP:0005214
10 lymphadenopathy 56 32 Occasional (29-5%) HP:0002716
11 abnormality of the peritoneum 56 32 Very frequent (99-80%) HP:0002585
12 abnormality of the abdominal wall 56 32 Very frequent (99-80%) HP:0004298

Drugs & Therapeutics for Pseudomyxoma Peritonei

Drugs for Pseudomyxoma Peritonei (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
2
Fluorouracil Approved Phase 2 51-21-8 3385
3
Oxaliplatin Approved, Investigational Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
4
Amoxicillin Approved, Vet_approved Phase 2 26787-78-0 33613 2171
5
Clarithromycin Approved Phase 2 81103-11-9 84029
6
Lansoprazole Approved, Investigational Phase 2 103577-45-3 3883
7
nivolumab Approved Phase 2 946414-94-4
8
leucovorin Approved, Nutraceutical Phase 2,Phase 1 58-05-9 54575, 6560146 143
9 Anti-Infective Agents Phase 2,Phase 1
10 Antimetabolites Phase 2,Phase 1
11 Antimetabolites, Antineoplastic Phase 2,Phase 1
12 Immunosuppressive Agents Phase 2,Phase 1
13 Antacids Phase 2
14 Anti-Bacterial Agents Phase 2
15 Antibiotics, Antitubercular Phase 2
16 Antitubercular Agents Phase 2
17 Anti-Ulcer Agents Phase 2
18 Cytochrome P-450 CYP3A Inhibitors Phase 2
19 Cytochrome P-450 Enzyme Inhibitors Phase 2
20
Dexlansoprazole Phase 2 138530-94-6, 103577-45-3 9578005
21 Gastrointestinal Agents Phase 2
22
Proton pump inhibitors Phase 2
23 Antibodies Phase 2
24 Antibodies, Monoclonal Phase 2
25 Immunoglobulins Phase 2
26 Alkylating Agents Phase 2
27 Mitomycins Phase 2
28 Nucleic Acid Synthesis Inhibitors Phase 2
29
Carboplatin Approved Phase 1 41575-94-4 10339178 498142 38904
30
Gemcitabine Approved Phase 1 95058-81-4 60750
31
Floxuridine Approved Phase 1 50-91-9 5790
32
Levoleucovorin Approved Phase 1 68538-85-2
33 Antiviral Agents Phase 1
34 Antidotes Phase 1
35 Calcium, Dietary Phase 1
36 Liver Extracts Phase 1
37 pancreatic polypeptide Phase 1
38 Protective Agents Phase 1
39 Cola Nutraceutical Phase 1
40
Doxorubicin Approved, Investigational 23214-92-8 31703
41
Ifosfamide Approved 3778-73-2 3690
42
Folic Acid Approved, Nutraceutical, Vet_approved 59-30-3 6037
43
Doxil Approved June 1999 31703
44 Coagulants
45 Hemostatics
46 Isophosphamide mustard
47 Thrombin
48 Folate Nutraceutical
49 Vitamin B9 Nutraceutical

Interventional clinical trials:

(show all 17)
id Name Status NCT ID Phase
1 Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin Recruiting NCT02387203 Phase 2
2 HIPEC Using High Intra-abdominal Pressure Recruiting NCT02949791 Phase 2
3 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
4 Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C Enrolling by invitation NCT02040142 Phase 2
5 A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis Terminated NCT00352755 Phase 2
6 Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer Completed NCT01652794 Phase 1
7 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1
8 Results of CRS and Debulking in PMP Patients Unknown status NCT01427101
9 Thrombin Generation and Platelet Activation in CRS/HIPEC Completed NCT03034850
10 Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients Completed NCT02374411
11 Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Completed NCT01126346
12 Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer Completed NCT01764789
13 Crossover Trial of Systemic Chemotherapy in Patients With Metastatic Well-Differentiated Mucinous Appendiceal Adenocarcinomas With Pseudomyxoma Peritonei Recruiting NCT01946854
14 Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed Recruiting NCT01617382
15 Gastrointestinal Microbiome Study of Appendiceal Cancer Recruiting NCT02599116
16 Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies Recruiting NCT02073500
17 French National Registry of Rare Peritoneal Surface Malignancies Active, not recruiting NCT02834169

Search NIH Clinical Center for Pseudomyxoma Peritonei

Cochrane evidence based reviews: pseudomyxoma peritonei

Genetic Tests for Pseudomyxoma Peritonei

Anatomical Context for Pseudomyxoma Peritonei

MalaCards organs/tissues related to Pseudomyxoma Peritonei:

39
Appendix, Colon, Small Intestine, Ovary, Pancreas, Testes, Breast

Publications for Pseudomyxoma Peritonei

Articles related to Pseudomyxoma Peritonei:

(show top 50) (show all 566)
id Title Authors Year
1
Early Postoperative Intraperitoneal Chemotherapy for Low-Grade Appendiceal Mucinous Neoplasms with Pseudomyxoma Peritonei: Is it Beneficial? ( 27718032 )
2017
2
Synchronous Ovarian and Appendiceal Mucinous Neoplasms in the Absence of Pseudomyxoma Peritonei. ( 27870702 )
2017
3
The modified Glasgow prognosis score predicts for overall and disease-free survival following cytoreductive surgery and HIPEC in patients with pseudomyxoma peritonei of appendiceal origin. ( 27866811 )
2017
4
Carbonic anhydrase II: a novel biomarker for pseudomyxoma peritonei. ( 28233447 )
2017
5
Preoperative CT and MRI prediction of non-resectability in patients treated for pseudomyxoma peritonei from mucinous appendiceal neoplasms. ( 26856956 )
2016
6
Pseudomyxoma Peritonei: Symptom Control and Objective Radiological Response after Treatment with Lanreotide Autogel. ( 26933420 )
2016
7
FDG-PET/ceCT is useful to predict recurrence of Pseudomyxoma peritonei. ( 26907364 )
2016
8
Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study. ( 27352203 )
2016
9
Incidence of leukopenia after intraperitoneal vs combined intravenous/intraperitoneal chemotherapy in pseudomyxoma peritonei. ( 27602245 )
2016
10
Pathology of Mucinous Appendiceal Tumors and Pseudomyxoma Peritonei. ( 27065718 )
2016
11
Should total gastrectomy and total colectomy be considered for selected patients with severe tumor burden of pseudomyxoma peritonei in cytoreductive surgery? ( 27241925 )
2016
12
Pseudomyxoma Peritonei in a Patient with History of Breast Cancer. ( 26996187 )
2016
13
Appendicular mucinous adenocarcinoma associated with pseudomyxoma peritonei, a rare and difficult imaging diagnosis. ( 27239665 )
2016
14
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei and Appendix Tumours. ( 27065707 )
2016
15
Advanced Pseudomyxoma Peritonei Requiring Gastrectomy to Achieve Complete Cytoreduction Results in Good Long-Term Oncologic Outcomes. ( 27380645 )
2016
16
Long-term survival after aggressive treatment of relapsed serosal or distant pseudomyxoma peritonei. ( 27646440 )
2016
17
Pseudomyxoma peritonei of a mature ovarian teratoma caused by mismatch repair deficiency in a patient with Lynch syndrome: a case report. ( 27938333 )
2016
18
A case of pseudomyxoma peritonei: visualization of septa using diffusion-weighted images with low b values. ( 26984750 )
2016
19
Significance of epithelial cell clusters in pseudomyxoma peritonei. ( 27121698 )
2016
20
Patient-derived xenograft mouse models of pseudomyxoma peritonei recapitulate the human inflammatory tumor microenvironment. ( 26833741 )
2016
21
A rare, low-grade appendiceal mucinous neoplasm (Pseudomyxoma peritonei) with ossification: A case report with morphoproteomic analysis of bone formation. ( 27712976 )
2016
22
Mucinous Balls Tangled With Mesothelial Cells and MUC2-Positive Cancer Cells in the Ascites of Pseudomyxoma Peritonei. ( 27079739 )
2016
23
Incidentally discovered low-grade appendiceal mucinous neoplasm: a precursor to pseudomyxoma peritonei. ( 27980743 )
2016
24
Can a Benefit be Expected from Surgical Debulking of Unresectable Pseudomyxoma Peritonei? ( 26678404 )
2016
25
Expression of CEA, CA19-9, CA125, and EpCAM in pseudomyxoma peritonei. ( 27038681 )
2016
26
Pseudomyxoma peritonei with intrathoracic extension: a rare disease with rarer presentation from low-grade mucinous adenocarcinoma of the appendix. ( 26729823 )
2016
27
Huge pseudomyxoma peritonei: Surgical strategies and procedures to employ to optimize the rate of complete cytoreductive surgery. ( 26868165 )
2016
28
Erratum to: FDG-PET/ceCT is useful to predict recurrence of Pseudomyxoma peritonei. ( 27044382 )
2016
29
Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei. ( 26193962 )
2015
30
Endometrial involvement in pseudomyxoma peritonei secondary to low-grade appendiceal mucinous neoplasm: report of 2 cases. ( 25760906 )
2015
31
Palliative surgery for pseudomyxoma peritonei. ( 26232048 )
2015
32
Transformation of low-grade mucinous neoplasm of the appendix with pseudomyxoma peritonei to high-grade sarcomatoid carcinoma. ( 26015826 )
2015
33
A rare cause of ascites: pseudomyxoma peritonei and a review of the literature. ( 25838904 )
2015
34
Elevated tumour markers are normalized in most patients with pseudomyxoma peritonei one week after complete tumour removal. ( 25704482 )
2015
35
Palliative parenteral nutrition use in patients with intestinal failure as a consequence of advanced pseudomyxoma peritonei: a case series. ( 26105107 )
2015
36
Case of intraperitoneal sepsis secondary to rupture of the appendix on the background of pseudomyxoma peritonei. ( 25685336 )
2015
37
Global gene expression in pseudomyxoma peritonei, with parallel development of two immortalized cell lines. ( 25929336 )
2015
38
Ultrasonographic Features of Pseudomyxoma Peritonei and TheirComparison with Computed Tomographic Findings. ( 26564459 )
2015
39
Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Arising from Urachus. ( 26714961 )
2015
40
Pseudomyxoma peritonei extending to the lower extremity: a case report. ( 26187269 )
2015
41
Bicytopenia as a paraneoplastic syndrome for pseudomyxoma peritonei. Hematologic manifestations of a subtle disease. ( 25767403 )
2015
42
Two independent primary mucinous tumors involving the appendix and ovary accompanied with acellular pseudomyxoma peritonei. ( 26617936 )
2015
43
Correlation of Radiologic with Surgical Peritoneal Cancer Index Scores in Patients with Pseudomyxoma Peritonei and Peritoneal Carcinomatosis: How Well Can We Predict Resectability? ( 26162922 )
2015
44
Strategies for Preventing Pseudomyxoma Peritonei After Resection of a Mucinous Neoplasm of the Appendix. ( 26254392 )
2015
45
Ovarian strumal carcinoid containing appendiceal-type mucinous tumor patterns presenting as pseudomyxoma peritonei. ( 25760904 )
2015
46
Pseudomyxoma peritonei diagnosed 19a88years after appendicectomy. ( 26494720 )
2015
47
The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). ( 26026742 )
2015
48
A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process. ( 26492181 )
2015
49
Recommendations in the management of epithelial appendiceal neoplasms and peritoneal dissemination from mucinous tumours (pseudomyxoma peritonei). ( 26489426 )
2015
50
Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Arising from Urachus. ( 25572681 )
2015

Variations for Pseudomyxoma Peritonei

Cosmic variations for Pseudomyxoma Peritonei:

9 (show top 50) (show all 65)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM1035874 VHL peritoneum,appendix,other,pseudomyxoma peritonei c.430G>A p.G144R 7
2 COSM10659 TP53 peritoneum,appendix,other,pseudomyxoma peritonei c.817C>T p.R273C 7
3 COSM10771 TP53 peritoneum,appendix,other,pseudomyxoma peritonei c.749C>T p.P250L 7
4 COSM10648 TP53 peritoneum,appendix,other,pseudomyxoma peritonei c.524G>A p.R175H 7
5 COSM10777 TP53 peritoneum,appendix,other,pseudomyxoma peritonei c.715A>G p.N239D 7
6 COSM14122 SMAD4 peritoneum,appendix,other,pseudomyxoma peritonei c.1082G>A p.R361H 7
7 COSM1150828 SMAD4 peritoneum,appendix,other,pseudomyxoma peritonei c.1495T>C p.C499R 7
8 COSM1150895 SMAD4 peritoneum,appendix,other,pseudomyxoma peritonei c.1157G>A p.G386D 7
9 COSM4169157 SMAD2 peritoneum,appendix,other,pseudomyxoma peritonei c.1391C>T p.S464L 7
10 COSM1570338 RET peritoneum,appendix,other,pseudomyxoma peritonei c.2651A>T p.E884V 7
11 COSM12591 PIK3CA peritoneum,appendix,other,pseudomyxoma peritonei c.3127A>G p.M1043V 7
12 COSM763 PIK3CA peritoneum,appendix,other,pseudomyxoma peritonei c.1633G>A p.E545K 7
13 COSM4755600 PDGFRA peritoneum,appendix,other,pseudomyxoma peritonei c.1658C>T p.P553L 7
14 COSM580 NRAS peritoneum,appendix,other,pseudomyxoma peritonei c.181C>A p.Q61K 7
15 COSM521 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.35G>A p.G12D 7
16 COSM532 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.38G>A p.G13D 7
17 COSM539 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.44G>A p.G15D 7
18 COSM520 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.35G>T p.G12V 7
19 COSM527 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.37G>T p.G13C 7
20 COSM4169147 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.412G>A p.G138R 7
21 COSM522 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.35G>C p.G12A 7
22 COSM516 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.34G>T p.G12C 7
23 COSM1360888 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.28G>A p.G10R 7
24 COSM51382 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.50G>A p.S17N 7
25 COSM529 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.37G>C p.G13R 7
26 COSM517 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.34G>A p.G12S 7
27 COSM4169137 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.418C>T p.P140S 7
28 COSM1562184 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.25G>A p.V9I 7
29 COSM4169149 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.380C>T p.T127I 7
30 COSM4169153 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.389C>T p.A130V 7
31 COSM1169214 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.101C>T p.P34L 7
32 COSM3727814 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.91G>A p.E31K 7
33 COSM4169161 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.59C>T p.T20M 7
34 COSM27895 GNAS peritoneum,appendix,other,pseudomyxoma peritonei c.602G>A p.R201H 7
35 COSM27887 GNAS peritoneum,appendix,other,pseudomyxoma peritonei c.601C>T p.R201C 7
36 COSM302311 GNAS peritoneum,appendix,other,pseudomyxoma peritonei c.692G>A p.R231H 7
37 COSM4169145 GNAS peritoneum,appendix,other,pseudomyxoma peritonei c.643G>A p.D215N 7
38 COSM4169155 GNAS peritoneum,appendix,other,pseudomyxoma peritonei c.706C>T p.Q236* 7
39 COSM1685346 GNAS peritoneum,appendix,other,pseudomyxoma peritonei c.677G>A p.G226D 7
40 COSM4169159 GNAS peritoneum,appendix,other,pseudomyxoma peritonei c.596G>A p.R199H 7
41 COSM99221 GNAS peritoneum,appendix,other,pseudomyxoma peritonei c.602G>T p.R201L 7
42 COSM4386691 ATM peritoneum,appendix,other,pseudomyxoma peritonei c.3980T>G p.L1327* 7
43 COSM33765 AKT1 peritoneum,appendix,other,pseudomyxoma peritonei c.49G>A p.E17K 7
44 COSM1140133 peritoneum,appendix,other,pseudomyxoma peritonei c.35G>T p.G12V 7
45 COSM1135366 peritoneum,appendix,other,pseudomyxoma peritonei c.35G>A p.G12D 7
46 COSM1360887 peritoneum,appendix,other,pseudomyxoma peritonei c.28G>A p.G10R 7
47 COSM4169158 peritoneum,appendix,other,pseudomyxoma peritonei c.2525G>A p.R842H 7
48 COSM1140132 peritoneum,appendix,other,pseudomyxoma peritonei c.38G>A p.G13D 7
49 COSM4169138 peritoneum,appendix,other,pseudomyxoma peritonei c.29G>A p.G10E 7
50 COSM123397 peritoneum,appendix,other,pseudomyxoma peritonei c.2530C>T p.R844C 7

Expression for Pseudomyxoma Peritonei

Search GEO for disease gene expression data for Pseudomyxoma Peritonei.

Pathways for Pseudomyxoma Peritonei

GO Terms for Pseudomyxoma Peritonei

Cellular components related to Pseudomyxoma Peritonei according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 Golgi lumen GO:0005796 8.92 MUC1 MUC2 MUC5AC MUC6

Biological processes related to Pseudomyxoma Peritonei according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 striated muscle cell differentiation GO:0051146 9.26 CDH2 KRAS
2 O-glycan processing GO:0016266 9.26 MUC1 MUC2 MUC5AC MUC6
3 maintenance of gastrointestinal epithelium GO:0030277 9.16 MUC2 MUC6
4 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.02 KRAS MUC1 MUC2 MUC5AC MUC6

Sources for Pseudomyxoma Peritonei

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....